Ушбу ишга иқтибос қилган ишлар

2 та иш

Иш: Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222

1. Structure-driven design and precision translation of functionally diverse isatin-based CDK2 inhibitors: Advances in SAR, polypharmacology, and biomarker-guided cancer therapy

   Safia Obaidur Rab, A. Al-Shahrani, Lalji Baldaniya +9

   МақолаCancer-related Molecular PathwaysJournal of Molecular Structure20250 иқтибос

   ABIABI:AkademIndex/openalex/2025.article.010865

2. From cell cycle control to cancer therapy: exploring the role of CDK1 and CDK2 in tumorigenesis

   Jitendra Gupta, Bahaa Ibrahim Saeed, Ashok Kumar Bishoyi +7

   Шарҳ мақолаRNA modifications and cancerMedical Oncology20250 иқтибос

   ABIABI:AkademIndex/openalex/2025.review-article.000027